Ikena Oncology: Funding, Investors & Team (Sep 2026)
Ikena Oncology discovers and develops biomarker-driven therapies for cancer patients. The company focuses on developing novel cancer therapies that drive the formation and spread of cancer. Ikena Oncology provides medical needs by discovering chemistry, translational science, and patient-centric drug development.
Ikena Oncology has raised $115M across 2 funding rounds on record, the most recent an undisclosed round of $75.0M announced in Dec 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ikena Oncology Company Profile and Key Stats
Latest funding round on record: Dec 2024.
Ikena Oncology Funding Rounds
Ikena Oncology raised $40.0M in an undisclosed round announced in May 2023.
1.6 years later, an undisclosed round of $75.0M was announced in Dec 2024.
Ikena Oncology Founders and Leadership Team
No contact details are on record for this team yet.
Ikena Oncology Funding Compared to Other Biotechnology Startups
Ikena Oncology's latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ikena Oncology in Biotechnology and Boston
Companies Similar to Ikena Oncology
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Ikena Oncology Funding FAQs
What does Ikena Oncology do?
Ikena Oncology discovers and develops biomarker-driven therapies for cancer patients. The company focuses on developing novel cancer therapies that drive the formation and spread of cancer. Ikena Oncology provides medical needs by discovering chemistry, translational science, and patient-centric drug development.
How much funding has Ikena Oncology raised?
Ikena Oncology has raised $115M across 2 rounds on record. The most recent is an undisclosed round of $75.0M announced in Dec 2024.
When did Ikena Oncology last raise funding?
Ikena Oncology's most recent funding round on record is an undisclosed round of $75.0M, announced in Dec 2024.
Who founded Ikena Oncology?
FundedIQ lists Karen Mcgovern (Founder) at Ikena Oncology.
Where is Ikena Oncology headquartered?
Ikena Oncology is based in Boston, Massachusetts, United States.
How many employees does Ikena Oncology have?
Ikena Oncology is in the 101-250 employee band.
How does Ikena Oncology's funding compare to other Biotechnology startups?
Ikena Oncology's latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Ikena Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ikena Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.